Global Critical Care Therapeutics Market 2017-2021
About Critical Care Therapeutics
Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.
Technavio’s analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Critical Care Therapeutics Market 2017-2021
Technavio recognizes the following companies as the key players in the global critical care therapeutics market: CSL Behring, Grifols, Kedrion Biopharma, Octapharma, and Shire.
Other Prominent Vendors in the market are: Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, and Ventria Bioscience.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is establishment of plasma fractionation facilities in emerging economies by global players. Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations. However, currently the presence of plasma fractionation facilities is very much limited to China within emerging countries, but in future, the incentives listed above should be driving the vendors to establish more facilities in these regions. For instance, in 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, would drive global players to open number of such facilities in the region.”
According to the report, one driver in market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. For instance, according to the CDC 2015 report, around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year.
Further, the report states that one challenge in market is high regulations of plasma products. Manufacturers of critical care therapeutics need to follow rigorous and distinct sets of regulatory guidelines like the adherence to current good manufacturing practices (cGMP) during the donation and processing of the plasma products. These guidelines are applied both for the collection of plasma from donors and during the fractionation of plasma-derived products along with the manufacture and production of the final product. Various regulatory bodies like the WHO; European Commission Directorate-General for Health and Consumers (DG SANCO), EMA, EDQM, and NCAs in the EU; HHS, US FDA, and the CDC, in the US; and Anvisa and COFEPRIS in ROW regulate these processes. Also, the approval process for plasma products is very long. For instance, in China, the plasma products have to go through 10 different stages, which takes a minimum of 22-28 months to receive approval for commercialization in the market by the CFDA. Since the plasma collection and manufacturing units are required to follow these guidelines, which requires high cost and efficiency, many of the new players are unable to enter the market, thus hindering the market growth.
CSL Behring, Grifols, Kedrion Biopharma, Octapharma, Shire, Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook